Tenofovir disoproxil fumarate - BrightGene Bio-Medical Technology/Jiangsu Chia Tai Tianqing Pharmaceutical

Drug Profile

Tenofovir disoproxil fumarate - BrightGene Bio-Medical Technology/Jiangsu Chia Tai Tianqing Pharmaceutical

Latest Information Update: 26 May 2016

Price : $50

At a glance

  • Originator BrightGene Bio-medical technology
  • Developer Chia Tai Tianqing Pharmaceutical Group
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Hepatitis B

Most Recent Events

  • 01 Sep 2014 Clinical trials in Hepatitis B in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top